Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher S Hackett

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 24, 2007
Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastomaAndy J Cheng, Ngan Ching Cheng, Jette Ford, et al.
Molecular Therapy. Oncology|September 23, 2024
TYRP1 directed CAR T cells control tumor progression in preclinical melanoma modelsChristopher S Hackett, Daniel Hirschhorn, Meixian S Tang, et al.
Transplantation and Cellular Therapy|June 17, 2026
Real-world assessment of prophylactic anakinra on neurotoxicity and cytokine release syndrome after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysisNeela Easton, Mia Andreoli, Herman van Besien, et al.
Cancer Discovery|February 1, 2015
The genetics of splicing in neuroblastomaJustin Chen, Christopher S Hackett, Shile Zhang, et al.
Cell Reports|May 29, 2026
Tumor-intrinsic expression of signal regulatory protein α contributes to the suppression of anti-tumor immune responsesChien-Huan Weng, Chana Schochet, Vincent Panneton, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuitFei Yi, Tal Cohen, Natalie Zimmerman, et al.
Cancer Research|October 22, 2009
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethalityLara S Collier, David J Adams, Christopher S Hackett, et al.
Nature Medicine|September 28, 2010
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastomaAlexander Swarbrick, Susan L Woods, Alexander Shaw, et al.
Genes & Development|August 3, 2012
Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamicsXi Huang, Adrian M Dubuc, Rintaro Hashizume, et al.
Nature Cancer|July 22, 2025
CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuitFei Yi, Tal Cohen, Natalie Zimmerman, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
European Journal of Cancer (Oxford, England : 1990)|April 24, 2007
Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastomaAndy J Cheng, Ngan Ching Cheng, Jette Ford, et al.
Molecular Therapy. Oncology|September 23, 2024
TYRP1 directed CAR T cells control tumor progression in preclinical melanoma modelsChristopher S Hackett, Daniel Hirschhorn, Meixian S Tang, et al.
Transplantation and Cellular Therapy|June 17, 2026
Real-world assessment of prophylactic anakinra on neurotoxicity and cytokine release syndrome after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysisNeela Easton, Mia Andreoli, Herman van Besien, et al.
Cancer Discovery|February 1, 2015
The genetics of splicing in neuroblastomaJustin Chen, Christopher S Hackett, Shile Zhang, et al.
Cell Reports|May 29, 2026
Tumor-intrinsic expression of signal regulatory protein α contributes to the suppression of anti-tumor immune responsesChien-Huan Weng, Chana Schochet, Vincent Panneton, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuitFei Yi, Tal Cohen, Natalie Zimmerman, et al.
Cancer Research|October 22, 2009
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethalityLara S Collier, David J Adams, Christopher S Hackett, et al.
Nature Medicine|September 28, 2010
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastomaAlexander Swarbrick, Susan L Woods, Alexander Shaw, et al.
Genes & Development|August 3, 2012
Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamicsXi Huang, Adrian M Dubuc, Rintaro Hashizume, et al.
Nature Cancer|July 22, 2025
CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuitFei Yi, Tal Cohen, Natalie Zimmerman, et al.
Pageof 3